Furthermore, SGLT-2 inhibitors improve metabolic status, reduce body weight, control blood pressure, and improve lipid profiles, indirectly alleviating chronic inflammation and fibrosis, which ultimately benefits the overall renal prognosis in IgA nephropathy patients (121). Here, SLC5A2 is linked to IgA glomerulonephritis.